Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- CIN1
- AIS
- Cervical Cancer
- CIN2
- CIN3
- Genital Wart
- Vulvar Cancer
- Vaginal Cancer
- VaIN1
- VaIN2
- VaIN3
- VIN 1
- VIN 2
- VIN 3
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Participant, Investigator)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 20 years and 45 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04422366
- Collaborators
- Not Provided
- Investigators
- Not Provided